Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

Growing evidence suggest that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. A 17-TFs related prognostic signature was con...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-03, Vol.11 (1), p.7207-7207, Article 7207
Main Authors: Li, He, Wu, Nayiyuan, Liu, Zhao-Yi, Chen, Yong-Chang, Cheng, Quan, Wang, Jing
Format: Article
Language:English
Subjects:
631/67/1517
631/67/70
Chemotherapy
Cisplatin
Cytotoxicity
Doxorubicin
Etoposide
Gemcitabine
Gene expression
Genomic analysis
Humanities and Social Sciences
Immune response
Immunotherapy
Inflammation
Leukocyte migration
Lymphocytes
Lymphocytes T
multidisciplinary
Nomograms
Ovarian cancer
Paclitaxel
PD-1 protein
Science
Science (multidisciplinary)
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Growing evidence suggest that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. A 17-TFs related prognostic signature was constructed using lasso cox regression and validated in the TCGA and GEO cohorts. Consensus clustering analysis was applied to establish a cluster model. The 17-TFs related prognostic signature, risk score and cluster models were effective at accurately distinguishing the overall survival of SOC. Analysis of genomic alterations were used to elaborate on the association between the 17-TFs related prognostic signature and genomic aberrations. The GSEA assay results suggested that there was a significant difference in the inflammatory and immune response pathways between the high-risk and low-risk score groups. The potential immune infiltration, immunotherapy, and chemotherapy responses were analyzed due to the significant difference in the regulation of lymphocyte migration and T cell-mediated cytotoxicity between the two groups. The results indicated that patients with low-risk score were more likely to respond anti-PD-1, etoposide, paclitaxel, and veliparib but not to gemcitabine, doxorubicin, docetaxel, and cisplatin. Also, the prognostic nomogram model revealed that the risk score was a good prognostic indicator for SOC patients. In conclusion, we explored the prognostic values of TFs in SOC and developed a 17-TFs related prognostic signature to predict the survival of SOC patients.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-86294-z